4 July 2014
Helicon Health’s web based package of services – HeliconHeart- is cited as an example of good practice in the new NICE guidelines on Atrial Fibrillation (AF), published on 18 June 2014.
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting some 800, 000 patients in the UK alone. If left untreated, atrial fibrillation is a significant risk factor for stroke and other illnesses.
HeliconHeart is an integrated package of web-based services tailored to assist the management of patients with atrial fibrillation, who, typically need both anticoagulation to reduce the risk of stroke and other measures to control the heart rate and rhythm.
David Patterson, Chief Executive, Helicon Health commented; “We are delighted that our approach to meeting the needs of patients with AF has been recognized in this way. Helicon Heart covers all elements of the NICE guidelines on AF so we are well placed to meet the needs of healthcare providers as they shape their anticoagulation services and work towards the better management of patients with AF.”
Mr Cengiz Tarhan, Managing Director of UCLB commented; “NICE is a world leader in setting standards for quality healthcare, this is a great reflection on Helicon Health and their unique HeliconHeart package.”
About Helicon Health
Helicon Health is committed to facilitating shared care for the management of long-term conditions. The company’s aim is to ensure that, as there is an increase in the number of patients managed outside the hospital environment, they also enhance the quality of care.
The Helicon Health goal is to help commissioners move towards a distributed service where the complex patients (10 – 15%) are managed in the hospital setting whilst the rest are either self-testing and self-managing, or being managed by the GP, an outreach service or their community pharmacy.
For more information, visit: www.heliconhealth.co.uk
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit: www.uclb.com